Viking Therapeutics Inc Stock

Shares of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, are down by 34% this year. This poor performance may suggest that recent company-specific developments have rendered the stock less

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% return

A major C-suite change at a potential competitor was a key factor behind the rise of Viking Therapeutics (NASDAQ: VKTX) stock on Friday, which closed the trading session 3% higher. That figure was

Investing in promising companies before their stock prices soar is an excellent recipe for earning life-changing returns. However, with hundreds of companies vying for investors' attention

Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years. Some of them didn't even exist that long ago. Others were only a fraction of their current size.

One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics' (NASDAQ: VKTX) stock

Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was a winning stock this week. Over the course of the past five trading days

Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports

The pharmaceutical and biotechnology business tends to be about hitting home runs more than just getting on base. A highly successful drug, sometimes referred to as a blockbuster, can build up a

Viking Therapeutics (NASDAQ: VKTX) was one of the hottest biotech stocks of 2024; its shares soared last year following excellent clinical progress. However, things have been very different in 2025

Shares of Viking Therapeutics (NASDAQ: VKTX) jumped 12.5% through 11:40 a.m. ET on Tuesday on further support from Wall Street analysts.

Viking stock inched higher Monday after Truist Securities

Viking Therapeutics (NASDAQ: VKTX) stock inched 2.3% higher through 10:20 a.m. ET Monday, and for a most curious reason.

Truist Securities analyst Joon Lee just lowered his price target on the

It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (NYSE: LLY) stock is off to the races!

This morning, the Indianapolis-based pharmaceutical giant announced that its new GLP-1 weight loss pill

Equity markets have had a rough go of it this year due to President Trump's macroeconomic policies. Though it can be challenging to navigate this environment, one way to make the best of it is to

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (NASDAQ: VKTX), the turbulence has been extremely challenging thus far. The stock

When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with

After back-to-back years of strong returns for cruise line stocks, this year has been enough to make investors seasick. The three largest cruise line operators are trading 29%, 17%, and 35% lower in

Viking Therapeutics (NASDAQ: VKTX) is a healthcare company that possesses a lot of growth potential. And last year, its shares rose by 116%, as investors were bullish on its prospects.

This year

One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that perform well tend to attract plenty of attention that bids up their share